Navigation Links
Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
Date:12/28/2007

nt of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties the Company faces, see the reports it has filed with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.

Contacts:

Jennifer Snyder (media) Kyle Kuvalanka (investors)

(617) 448-0281 (857) 498-0818


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
2. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
3. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
4. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
5. Life Sciences Leader Joins Millennium Board of Directors
6. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
7. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
10. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a ... today announced that it has received notification from The ... been approved for listing on the NASDAQ Global Market. ... 2009 on NASDAQ at market open under the symbol ...
... 6 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a ... today announced it has received US$2,500,000 from MannKind ... the option agreement and issuance of 2,400,000 units ... The transaction provides MannKind with the option to ...
... Star Scientific (Nasdaq :STSI) announced today that its ... its Star Tobacco, Inc. subsidiary, recently completed a ... dissolvable smokeless tobacco to relieve cigarette withdrawal symptoms ... (NRT). The study, which included 49 cigarette smokers, ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market 2SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin 2SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 2Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 4
(Date:4/15/2014)... Biologists at UC San Diego have succeeded in ... hormone responsible for growth and resistance to drought. ... studies to determine how the hormone helps plants ... by the continuing increase in the atmosphere,s carbon ... achievement appears in the April 15 issue of ...
(Date:4/15/2014)... Looking at the question of how social behavior has ... universities in Mainz and Basel have gained new insights ... simply compete for food. Rather the siblings share what ... absent," explained Dr. Jol Meunier of the Evolutionary Biology ... University of Mainz (JGU). The team of biologists from ...
(Date:4/15/2014)... (April 15, 2014) The American Association of Anatomists ... All awards will be presented during the Closing ... Hotel on Tuesday, April 29th at 7:30 p.m. during ... , The 2014 award winners are: , ... PhD, of the Icahn School of Medicine at Mount ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Sibling cooperation in earwig families gives clues to early evolution of social behavior 2American Association of Anatomists 2014 award winners 2
... Spanish scientists have analysed the temperature and salt levels of ... the evolution of each variable. Their research shows that, since ... hotter and saltier, and that, since the 1990s, this process ... deep layer of the Western Mediterranean increases by 0.002C, and ...
... Miami (UM) has been selected to receive a $1.4 ... to strengthen the UM undergraduate science education program. The ... will use the resources to help attract first-generation college ... sciences to pursue careers in science. , "HHMI ...
... of Oxford and Royal Holloway University of London have discovered that ... works best if applied to young plants and is enhanced by ... (20 May) in the open-access journal PLoS Pathogens . ... is a common method for controlling a variety of insect ...
Cached Biology News:Temperature and salt levels of the Western Mediterranean are on the increase 2UM receives 5th consecutive Howard Hughes Medical Institute grant for science education 2Study uncovers optimal ecology of bioinsecticide 2
...
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: